UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Nature medicine, 2023-05, Vol.29 (5), p.1180-1190

2023

Volltextzugriff (PDF)

Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB90-AB90

2017

Volltextzugriff (PDF)

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Journal of allergy and clinical immunology, 2024-07, Vol.154 (1), p.184-194

2024

Volltextzugriff (PDF)

Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma

Journal of allergy and clinical immunology, 2024-07, Vol.154 (1), p.101-110

2024

Volltextzugriff (PDF)

Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

The lancet respiratory medicine, 2024-01, Vol.12 (1), p.45-54

2024

Volltextzugriff (PDF)

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function

Journal of asthma and allergy, 2020-01, Vol.13, p.701-711

2020

Volltextzugriff (PDF)

Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis

The Annals of pharmacotherapy, 2005-12, Vol.39 (12), p.1984

2005

Volltextzugriff (PDF)

Long-term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide

CHEST pulmonary, 2024-07, p.100072, Article 100072

2024

Volltextzugriff (PDF)

The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma

Respiratory medicine: X, 2020-11, Vol.2, p.100010, Article 100010

2020

Volltextzugriff (PDF)

Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma

Annals of allergy, asthma, & immunology, 2021-05, Vol.126 (5), p.584-592.e1

2021

Volltextzugriff (PDF)

Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-04, Vol.10 (4), p.1086-1095.e5

2022

Volltextzugriff (PDF)

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

Advances in therapy, 2018-05, Vol.35 (5), p.737-748

2018

Volltextzugriff (PDF)

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Rhinology, 2020-02, Vol.58 (1), p.10-17

2020

Volltextzugriff (PDF)

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2019-09, Vol.7 (7), p.2447-2449.e2

2019

Volltextzugriff (PDF)

A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019-02, Vol.143 (2), p.AB433-AB433

2019

Volltextzugriff (PDF)

Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019-02, Vol.143 (2), p.AB422-AB422

2019

Volltextzugriff (PDF)

Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB97-AB97

2019

Volltextzugriff (PDF)

Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB97-AB97

2019

Volltextzugriff (PDF)

Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma

The Annals of pharmacotherapy, 2005-12, Vol.39 (12), p.1977

2005

Volltextzugriff (PDF)

Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids

Current medical research and opinion, 2005-08, Vol.21 (8), p.1281-1289

2005

Volltextzugriff (PDF)

Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD

Chest, 2004-10, Vol.126 (4), p.709S-709S

2004

Volltextzugriff (PDF)

Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing

The American review of respiratory disease, 1990-07, Vol.142 (1), p.84

1990

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials

Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma

Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function

Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis

Long-term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide

The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma

Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma

Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD

A Randomized Phase 3 Study, Sinus-52, Evaluating the Efficacy and Safety of Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps

Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study

Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Dupilumab Suppresses Inflammatory Biomarkers in Asthma Patients With or Without Allergic Rhinitis: Post Hoc Analysis of the LIBERTY ASTHMA QUEST Study

Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma

Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids

Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, and quality of life and reduces exacerbations in patients with COPD

Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing

Suchergebnisse filtern